Topical immunization strategies

Mucosal Immunology

Volumn 3, Issue 6, 2010, Pages 545-555

  Czerkinsky, C ^a   Holmgren, J ^b  

^a International Vaccine Institute   (South Korea)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL VECTOR; CAMPYLOBACTER WHOLE CELL VACCINE; CCL28 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR9; CHOLERA TOXIN; CHOLERA TOXIN A1 SUBUNIT; CHOLERA TOXIN A1 SUBUNIT STAPHYLOCOCCUS AUREUS PROTEIN A DERIVATIVE DD FUSION PROTEIN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE MUTATED LT RG 192; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI VACCINE; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED POLIO VACCINE; INFLUENZA VACCINE; LT RG 192; LTK 63; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS VECTOR;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BELL PALSY; CELLULAR IMMUNITY; CHRONIC ENVIRONMENTAL ENTEROPATHY; CLINICAL TRIAL; DENDRITIC CELL; DEVELOPING COUNTRY; DIARRHEA; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; DRUG SAFETY; ENTEROPATHY; ENTEROTOXIGENIC ESCHERICHIA COLI; GASTROINTESTINAL MUCOSA; HELICOBACTER INFECTION; HUMAN; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; INTESTINAL M CELL; INTESTINE CELL; INTESTINE EPITHELIUM; LYMPH FOLLICLE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; LYMPHOID TISSUE; MUCOSA ASSOCIATED LYMPHOID TISSUE; MUCOSAL IMMUNITY; NONHUMAN; PEYER PATCH; PLASMABLAST; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN ENGINEERING; RESPIRATORY TRACT MUCOSA; REVIEW; SEXUALLY TRANSMITTED DISEASE; STOMACH MUCOSA; T LYMPHOCYTE; TISSUE DISTRIBUTION; TRANSCUTANEOUS IMMUNIZATION; TRAVELLER DIARRHEA; TROPICAL ENTEROPATHY; VACCINATION; VAGINA MUCOSA; VIRUS LIKE AGENT; VITAMIN DEFICIENCY;

EID: 77958155707     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2010.55     Document Type: Review

References (76)

1. Brandtzaeg, P. & Pabst, R. Let's go mucosal: communication on slippery ground. Trends Immunol. 25, 570-577 (2004).
2. Ogra, PL. Developmental aspects of the mucosal immune system: role of external environment, mucosal microflora and milk. Adv. Exp. Med. Biol. 639, 41-56 (2009).
3. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11, S45-S53 (2005).
4. Ogra, P. L. & Karzon, D. T. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J. Immunol. 102, 1423-1430 (1969).
5. Kiyono, H. & Fukuyama, S. NALT-vs. Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4, 699-710 (2004).
6. Mestecky, J. et al. Oral immunization: an update. Curr. Opin. Gastroenterol. 24, 713-719 (2008).
7. Kraehenbuhl, J. P. & Neutra, M. R. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 16, 301-332 (2000).
8. Jang, M. H. et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc. Natl. Acad. Sci. USA 101, 6110-6115 (2004).
9. Rescigno, M. & Di Sabatino, A. Dendritic cells in intestinal homeostasis and disease. J. Clin. Invest. 119, 2441-2450 (2009).
10. Mowat, A. M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 3, 331-341 (2003).
11. Rakoff-Nahoum, S. et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241 (2004).
12. Bilsborough, J. & Viney, J. L. Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. Gastroenterology 127, 300-309 (2004).
13. Fahlen-Yrlid, L. et al. CD11c (high) dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. J. Immunol. 183, 5032-5041 (2009).
14. Berg, E. L. et al. Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocyte traffic. Immunol. Rev. 108, 5-18 (1989).
15. Kunkel, E. J. & Butcher, E. C. Plasma-cell homing. Nat. Rev. Immunol. 3, 822-829 (2003).
16. Mora, J. R. et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 314, 1157-1160 (2006).
17. Stagg, A. J. et al. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur. J. Immunol. 32, 1445-1454 (2002).
18. Mora, J. R. et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424, 88-93 (2003).
19. Johansson-Lindbom, B. et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 202, 1063-1073 (2005).
20. Iwasaki, A. Mucosal dendritic cells. Annu. Rev. Immunol. 25, 381-418 (2007).
21. Wilson, E. & Butcher, E. C. CCL28 controls immunoglobulin (Ig) A plasma cell accumulation in the lactating mammary gland and IgA antibody transfer to the neonate. J. Exp. Med. 200, 805-809 (2004).
22. Czerkinsky, C. et al. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect. Immun. 59, 996-1001 (1991).
23. Eriksson, K. et al. Specific-antibody-secreting cells in the rectums and genital tracts of non-human primates following vaccination. Infect. Immun. 66, 5889-5896 (1998).
24. Jertborn, M. et al. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. 69, 4125-4128 (2001).
25. Johansson, E. L. et al. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 22, 984-990 (2004).
26. Kozlowski, P. A. et al. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65, 1387-1394 (1997).
27. Quiding, M. et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferongamma production and evokes local immunological memory. J. Clin. Invest. 88, 143-148 (1991).
28. Ogra, P. L. & Ogra, S. S. Local antibody response to poliovaccine in the human female genital tract. J Immunol. 110, 1307-1311 (1973).
29. Wassén, L. et al. Local intravaginal vaccination of the female genital tract. Scand. J. Immunol. 44, 408-414 (1996).
30. Ogra, P. L. & Karzon, D. T. Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine. J. Immunol. 102, 15-23 (1969).
31. Quiding-Järbrink, M. et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Invest. 99, 1281-1286 (1997).
32. Quiding-Järbrink, M. et al. Induction of compartmentalized B-cell responses in human tonsils. Infect. Immun. 63, 853-857 (1995).
33. Rudin, A. et al. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect. Immun. 66, 3390-3396 (1998).
34. Johansson, E. L. et al. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun. 69, 7481-7486 (2001).
35. Jertborn, M. et al. Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. Vaccine 12, 1078-1082 (1994).
36. Cuburu, N. et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25, 8598-8610 (2007).
37. Song, J. H. et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl. Acad. Sci. USA 105, 1644-1649 (2008).
38. Cuburu, N. et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J. Immunol. 183, 7851-7859 (2009).
39. Raghavan S. et al. Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect. Immun. in press (2010).
40. Song, J. H. et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J. Immunol. 182, 6851-6860 (2009).
41. Wang, W. et al. Identification of a novel CC chemokine (CCL28) which binds CCR10 (GPR2). J. Biol. Chem. 275, 22313-22323 (2000).
42. Pan, J. et al. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J. Immunol. 165, 2943-2949 (2000).
43. Kunkel, E. J. et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J. Clin. Invest. 111, 1001-1010 (2003).
44. Glenn, G. M. et al. Skin immunization made possible by cholera toxin. Nature 391, 851 (1998).
45. Glenn, G. M. & Kenney, R. T. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol. 304, 247-268 (2006).
46. Chang, S. Y. et al. Cutting edge: Langerin+ dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J. Immunol. 180, 4361-4365 (2008).
47. Herremans, T. M., Reimerink, J. H., Buisman, A. M., Kimman, T. G. & Koopmans, M. P. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J. Immunol. 162, 5011-5018 (1999).
48. Svennerholm, A. M. et al. Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand. J. Immunol. 6, 1345-1349 (1977).
49. Lavelle, E. C. & O'Hagan, D. T. Delivery systems and adjuvants for oral vaccines. Expert Opin. Drug. Deliv. 3, 747-762 (2006).
50. Cox, E. et al. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res. 37, 511-539 (2006).
51. Moyle, P. M. et al. Mucosal immunization: adjuvants and delivery systems. Curr. Drug. Deliv. 1, 385-396 (2004).
52. Nordly, P. et al. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin. Drug Deliv. 6, 657-672 (2009).
53. Kersten, G. F. & Crommelin, D. J. Liposomes and ISCOMs. Vaccine 21, 915-920 (2003).
54. Rao, R., Squillante, E. III. & Kim, K. H. Lipid-based cochleates: a promising formulation platform for oral and parenteral delivery of therapeutic agents. Crit. Rev. Ther. Drug Carrier Syst. 24, 41-61 (2007).
55. McDermott, M. R. et al. Polymer-grafted starch microparticles for oral and nasal immunization. Immunol. Cell Biol. 76, 256-262 (1998).
56. Eldridge, J. H. et al. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr. Top. Microbiol. Immunol. 146, 59-66 (1989).
57. Payne, L. G. et al. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm. Biotechnol. 6, 473-493 (1995).
58. Payne, L. G. et al. Poly[di (carboxylatophenoxy) phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16, 92-98 (1998).
59. Ada, G. Overview of vaccines and vaccination. Mol. Biotechnol. 29, 255-272 (2005).
60. Schiller, J. T. & Lowy, D. R. Vaccines to prevent infections by oncoviruses. Annu. Rev. Microbiol. in press (2010).
61. Treanor, J. Recombinant proteins produced in insect cells. Curr. Top. Microbiol. Immunol. 333, 211-225 (2009).
62. D'Aoust, M. A. et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 8, 607-619 (2010).
63. Ludwig, C. & Wagner, R. Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol. 18, 537-545 (2007).
64. Jennings, G. T. & Bachmann, M. F. The coming of age of virus-like particle vaccines. Biol. Chem. 389, 521-536 (2008).
65. Freytag, L. C. & Clements, J. D. Mucosal adjuvants. Vaccine 23, 1804-1813 (2005).
66. Holmgren, J. et al. Mucosal adjuvants and anti-infection and antiimmunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97, 181-188 (2005).
67. Lycke, N. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Ann. NY Acad. Sci.. 1029, 193-208 (2004).
68. Tagliabue, A. & Boraschi, D. Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171. Vaccine 11, 594-615 (1993).
69. Couch, R. B. Nasal vaccination, Escherichiacoli enterotoxin, and Bell's palsy. N. Engl. J. Med. 350, 860-861 (2004).
70. Lewis, D. J. et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichiacoli heat labile toxin. PLoS One. 4, e6999 (2009).
71. Agren, L. C. et al. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158, 3936-3946 (1997).
72. Adamsson, J. et al. Novel immunostimulatory agent based on CpG DNA linked to the non-toxic B subunit of cholera toxin. J. Immunol. 176, 4902-4913 (2006).
73. Mathan, V. I. Tropical sprue in southern India. Trans. R. Soc. Trop. Med. Hyg. 82, 10-14 (1988).
74. Nath, S. K. Tropical sprue. Curr. Gastroenterol. Rep. 7, 343-349 (2007).
75. Owens, S. R. & Greenson, J. K. The pathology of malabsorption: current concepts. Histopathology 50, 64-82 (2007).
76. Humphrey, J. H. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 374, 1032-1035 (2009).